GeneCentric to Present Data on the Purity Independent Subtyping of Tumor (PurIST℠) Test at AACR Pancreatic Conference
DURHAM, N.C.–(BUSINESS WIRE)–#GeneCentric—GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the poster presentation of further clinical validation data for PurIST℠, a novel RNA-expression test, in collaboration with Tempus. PurIST identifies patients with the classical subtype of pancreatic ductal adenocarcinoma (PDAC) that are likely to experience longer overall survival (OS) … [Read more…]
